These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 30185825)
1. BH3-only proteins are dispensable for apoptosis induced by pharmacological inhibition of both MCL-1 and BCL-X Greaves G; Milani M; Butterworth M; Carter RJ; Byrne DP; Eyers PA; Luo X; Cohen GM; Varadarajan S Cell Death Differ; 2019 Jun; 26(6):1037-1047. PubMed ID: 30185825 [TBL] [Abstract][Full Text] [Related]
2. Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML. Ewald L; Dittmann J; Vogler M; Fulda S Cell Death Dis; 2019 Dec; 10(12):917. PubMed ID: 31801941 [TBL] [Abstract][Full Text] [Related]
3. A direct comparison of selective BH3-mimetics reveals BCL-X Bierbrauer A; Jacob M; Vogler M; Fulda S Br J Cancer; 2020 May; 122(10):1544-1551. PubMed ID: 32203216 [TBL] [Abstract][Full Text] [Related]
4. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
5. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML. Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848 [TBL] [Abstract][Full Text] [Related]
6. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-X Kehr S; Haydn T; Bierbrauer A; Irmer B; Vogler M; Fulda S Cancer Lett; 2020 Jul; 482():19-32. PubMed ID: 32145345 [TBL] [Abstract][Full Text] [Related]
7. Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-x Peng Z; Gillissen B; Richter A; Sinnberg T; Schlaak MS; Eberle J Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542429 [TBL] [Abstract][Full Text] [Related]
8. ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins. Alcon C; Gómez Tejeda Zañudo J; Albert R; Wagle N; Scaltriti M; Letai A; Samitier J; Montero J Cells; 2021 Jul; 10(7):. PubMed ID: 34359829 [TBL] [Abstract][Full Text] [Related]
9. BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAF Hartman ML; Gajos-Michniewicz A; Talaj JA; Mielczarek-Lewandowska A; Czyz M Cancer Lett; 2021 Feb; 499():122-136. PubMed ID: 33259900 [TBL] [Abstract][Full Text] [Related]
10. Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma. Dengler MA; Teh CE; Thijssen R; Gangoda L; Lan P; Herold MJ; Gray DH; Kelly GL; Roberts AW; Adams JM Oncogene; 2020 Feb; 39(9):2009-2023. PubMed ID: 31772331 [TBL] [Abstract][Full Text] [Related]
11. DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis. Milani M; Byrne DP; Greaves G; Butterworth M; Cohen GM; Eyers PA; Varadarajan S Cell Death Dis; 2017 Jan; 8(1):e2552. PubMed ID: 28079887 [TBL] [Abstract][Full Text] [Related]
12. Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs. Diepstraten ST; Young S; La Marca JE; Wang Z; Kluck RM; Strasser A; Kelly GL Cell Death Differ; 2023 Apr; 30(4):1005-1017. PubMed ID: 36755070 [TBL] [Abstract][Full Text] [Related]
13. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma. de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186 [TBL] [Abstract][Full Text] [Related]
14. BH3-only proteins target BCL-xL/MCL-1, not BAX/BAK, to initiate apoptosis. Huang K; O'Neill KL; Li J; Zhou W; Han N; Pang X; Wu W; Struble L; Borgstahl G; Liu Z; Zhang L; Luo X Cell Res; 2019 Nov; 29(11):942-952. PubMed ID: 31551537 [TBL] [Abstract][Full Text] [Related]
15. Computational Design of BH3-Mimetic Peptide Inhibitors That Can Bind Specifically to Mcl-1 or Bcl-X Reddy CN; Manzar N; Ateeq B; Sankararamakrishnan R Biochemistry; 2020 Nov; 59(45):4379-4394. PubMed ID: 33146015 [TBL] [Abstract][Full Text] [Related]
16. Combined inhibition of aurora kinases and Bcl-xL induces apoptosis through select BH3-only proteins. Li J; Chen CH; O'Neill KL; Fousek-Schuller VJ; Black AR; Black JD; Zhang J; Luo X J Biol Chem; 2023 Feb; 299(2):102875. PubMed ID: 36621626 [TBL] [Abstract][Full Text] [Related]
17. The BH3 alpha-helical mimic BH3-M6 disrupts Bcl-X(L), Bcl-2, and MCL-1 protein-protein interactions with Bax, Bak, Bad, or Bim and induces apoptosis in a Bax- and Bim-dependent manner. Kazi A; Sun J; Doi K; Sung SS; Takahashi Y; Yin H; Rodriguez JM; Becerril J; Berndt N; Hamilton AD; Wang HG; Sebti SM J Biol Chem; 2011 Mar; 286(11):9382-92. PubMed ID: 21148306 [TBL] [Abstract][Full Text] [Related]
18. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104 [TBL] [Abstract][Full Text] [Related]
19. Selective BH3-mimetics targeting BCL-2, BCL-XL or MCL-1 induce severe mitochondrial perturbations. Henz K; Al-Zebeeby A; Basoglu M; Fulda S; Cohen GM; Varadarajan S; Vogler M Biol Chem; 2019 Jan; 400(2):181-185. PubMed ID: 29924730 [TBL] [Abstract][Full Text] [Related]
20. In non-transformed cells Bak activates upon loss of anti-apoptotic Bcl-XL and Mcl-1 but in the absence of active BH3-only proteins. Senft D; Weber A; Saathoff F; Berking C; Heppt MV; Kammerbauer C; Rothenfusser S; Kellner S; Kurgyis Z; Besch R; Häcker G Cell Death Dis; 2015 Nov; 6(11):e1996. PubMed ID: 26610208 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]